CAJ | 학술논문

目的探讨重组人腺病毒p53(rAd-p53)对胃癌细胞裸鼠移植瘤的抗肿瘤效应及相关不良反应.方法将胃癌细胞SGC-7901注射于裸鼠皮下制成动物模型,分别用rAd-p53和盐酸表阿霉素(EPI)进行治疗.rAd-p53治疗组剂量为10μl浓度1012vp/ml,EPI治疗组剂量为1.25mg/kg,各组每3周给药7次,以生理盐水为对照组.结果与对照组比较,rAd-p53治疗组和EPI治疗组肿瘤抑制率分别为80％和60％,差异有统计学意义(P＜0.01)；rAd-p53和EPI治疗组之间比较差异无统计学意义(P＞0.05).没有实验动物死亡,rAd-p53治疗组2只裸鼠出现肝脏不良反应,EPI治疗组1只裸鼠心脏不良反应,上述反应均有病理学观察证实.结论裸鼠体内实验证实rAd-p53对胃癌细胞具有抗肿瘤效应,但应注意其肝脏不良反应.
목적 탐토중조인선병독p53(rAd-p53)대위암세포라서이식류적항종류효응급상관불량반응.방법 장위암세포SGC-7901주사우라서피하제성동물모형,분별용rAd-p53화염산표아매소(EPI)진행치료.rAd-p53치료조제량위10μl농도1012vp/ml,EPI치료조제량위1.25mg/kg,각조매3주급약7차,이생리염수위대조조.결과 여대조조비교,rAd-p53치료조화EPI치료조종류억제솔분별위80％화60％,차이유통계학의의(P＜0.01)；rAd-p53화EPI치료조지간비교차이무통계학의의(P＞0.05).몰유실험동물사망,rAd-p53치료조2지라서출현간장불량반응,EPI치료조1지라서심장불량반응,상술반응균유병이학관찰증실.결론 라서체내실험증실rAd-p53대위암세포구유항종류효응,단응주의기간장불량반응.
Objective To investigate the inhibitory and side effects of recombinant Adenoviruswtp53 (tAd-p53) SGC-7901 on gastric cancer cells in vivo.Methods SGC-7901 cells were subcutaneously injected into the nude mice to establish xenograph models,which were treated with Gendicine,a recombinant human Ad-p53 injection (rAd-p53),and epirubicin hydrochloride (EPI),a cytotoxic chemotherapy agent.Results As compared with the blank control,treatment with rAd-p53 at the dose of 10 μl of 1012 vp/ml and EPI at the dose of 1.25 mg/kg,7 times every 3 weeks,resulted in 80％ and 60％ of tumor growth inhibition,respectively.The difference in rAd-p53 and EPI therapy group was not statistically significant.No animal death was observed,although 2 nude mice in rAd-p53 group developed liver toxicity and 1 nude mouse in EPI group developed cardiac toxicity,and the results were validated histopathologically.Conclusion The rAd-p53 has tumor inhibitory effect on gastric cancer cells,but the liver toxicity should be considered seriously.